PLASMA PROINSULIN IN RECENTLY DIAGNOSED TYPE-2 DIABETES-MELLITUS

被引:5
|
作者
SCHMIDLI, RS [1 ]
HAGAN, C [1 ]
SCOTT, RS [1 ]
LIVESEY, J [1 ]
FORBES, LV [1 ]
机构
[1] CHRISTCHURCH HOSP,LIPID & DIABET RES GRP,CHRISTCHURCH,NEW ZEALAND
关键词
PROINSULIN; INSULIN; TYPE-2; DIABETES-MELLITUS; IMMUNORADIOMETRIC ASSAY;
D O I
10.1016/0168-8227(93)90007-R
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
We measured levels of immunoreactive insulin (IRI) and proinsulin using a sensitive and specific immunoradiometric assay (IRMA), in non-obese recently diagnosed type 2 diabetic subjects. The proinsulin IRMA showed full cross reaction with intact proinsulin, des 31-32 proinsulin and des 64-65 proinsulin, but no reaction with insulin or C-peptide. In a group of 41 recently diagnosed non-obese Caucasian type 2 diabetic subjects (study group), mean fasting proinsulin levels were greater than that of 40 age and body mass index (BMI) matched controls (study group 17.4 +/- 2.0, controls 10.1 +/- 0.9 pmol-1, P < 0.001). Following a standard test meal, 30 and 60 min levels were not significantly different between groups but 90- and 120-min proinsulin levels were elevated in the study group. The maximum proinsulin to IRI ratio was 20% in the fasting state and did not differ between study and control groups. Proinsulin profiles were similar in subjects receiving oral hypoglycaemic agents and those on dietary treatment alone. Proinsulin did not correlate with indices of glycaemic control, total cholesterol, triglycerides or HDL cholesterol, but a relationship was observed with IRI before and after the meal. These results suggest that increased secretion of insulin precursors of low biological activity occurs in non obese recently diagnosed type 2 diabetic subjects under reasonably good glycaemic control; in such individuals the elevated levels of these precursors are approximately in proportion to the increase in IRI and are less than those reported in some previous studies.
引用
收藏
页码:133 / 138
页数:6
相关论文
共 50 条
  • [31] THE EFFECTS OF ORAL STANOZOLOL ON FIBRINOLYSIS IN TYPE-2 DIABETES-MELLITUS
    SMALL, M
    LOWE, GDO
    MACCUISH, AC
    FORBES, CD
    THROMBOSIS RESEARCH, 1986, 44 (02) : 253 - 259
  • [32] QT PROLONGATION IN TYPE-2 DIABETES-MELLITUS TREATED WITH GLIBENCLAMIDE
    IKEDA, T
    DIABETES & METABOLISM, 1994, 20 (06): : 565 - 567
  • [33] RENAL-TRANSPLANTATION IN PATIENTS WITH TYPE-2 DIABETES-MELLITUS
    HIRSCHL, MM
    NEPHROLOGY DIALYSIS TRANSPLANTATION, 1995, 10 : 58 - 60
  • [34] MANAGEMENT OF NEWLY DIAGNOSED NON-INSULIN-DEPENDENT (TYPE-2) DIABETES-MELLITUS - A RETROSPECTIVE AUDIT
    MARSIAJ, HI
    CATALANO, C
    SUM, CF
    HOME, PD
    ALBERTI, KGMM
    DIABETES RESEARCH AND CLINICAL PRACTICE, 1991, 12 (02) : 129 - 136
  • [35] DRUG-TREATMENT OF OBESITY IN TYPE-2 DIABETES-MELLITUS
    CARPENTER, MA
    BODANSKY, HJ
    DIABETIC MEDICINE, 1990, 7 (02) : 99 - 104
  • [36] COMBINED INSULIN AND SULFONYLUREA THERAPY FOR TYPE-2 DIABETES-MELLITUS
    RIDDLE, MC
    DIABETES RESEARCH AND CLINICAL PRACTICE, 1991, 11 (01) : 3 - 8
  • [37] PLATELET ACTIVITY AND FIBRINOLYSIS ARE ENHANCED IN TYPE-2 DIABETES-MELLITUS
    TAKADA, A
    URANO, T
    PIETRASZEK, MH
    TAKADA, Y
    THROMBOSIS AND HAEMOSTASIS, 1993, 69 (06) : 1271 - 1271
  • [38] PATHOGENESIS OF TYPE-2 DIABETES-MELLITUS - AN INTERPRETATION OF CURRENT DATA
    DAVIDSON, MB
    AMERICAN JOURNAL OF THE MEDICAL SCIENCES, 1986, 292 (01): : 35 - 39
  • [39] RENAL SIZE IN TYPE-2 DIABETES-MELLITUS - A CLINICOPATHOLOGIC STUDY
    DUMLER, F
    KUMAR, V
    ROMANSKI, RN
    CORTES, P
    LEVIN, NW
    KIDNEY INTERNATIONAL, 1985, 27 (01) : 137 - 137
  • [40] AQUEOUS-HUMOR DYNAMICS IN DIABETES-MELLITUS TYPE-2
    LARSSON, LI
    PACH, JM
    BRUBAKER, RF
    INVESTIGATIVE OPHTHALMOLOGY & VISUAL SCIENCE, 1993, 34 (04) : 922 - 922